author-photo

Saad Z. Usmani

Carolinas Healthcare System
University of Arkansas for Medical Sciences

460

Papers

12934

Citations

Citation Trend

Filter By

Papers (460) Sort By

Journal Conference Others

Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed By Ciltacabtagene Autoleucel Versus Vrd Followed By Lenalidomide and Dexamethasone (Rd) Maintenance in Patients with Newly Diagnosed Multiple Myeloma Not Intended for Transplant: A Randomized, Phase 3 Study (CARTITUDE-5)

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Phase II Trial of Elotuzumab in Combination with Carfilzomib, Lenalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM) after One Prior Line of Therapy

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma.

2021 Cancer Medicine
Show All
- Source
- Cite
- Save
Citations (0)
MM-119: Updated Results of Ciltacabtagene Autoleucel (Cilta-Cel), a B-Cell Maturation Antigen (BCMA)-Directed Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM)

2021 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (0)
A second autologous hematopoietic cell transplantation is a safe and effective salvage therapy in select relapsed or refractory AL amyloidosis patients.

2021 Bone Marrow Transplantation
Show All
- Source
- Cite
- Save
Citations (0)
The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.

2021
Show All
- Source
- Cite
- Save
Citations (1)
Cost per Responder Analysis to Assess the Value of CAR-T Therapy for Relapsed or Refractory Multiple Myeloma

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone: Update of the Phase 3 MAIA Trial

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Immune Therapies for Myeloma: The CARs Are Here but What's Next?

2021
- Sham Mailankody
- Saad Z. Usmani
Show All
- Source
- Cite
- Save
Citations (0)
Updated Results from CARTITUDE-1: Phase 1b/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed/Refractory Multiple Myeloma

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)